HemispheRx Biopharma, Helix regulatory update

HBP will supply Ampligen, a nucleic acid-based immunotherapy for HIV infection, under Canada's emergency release program. Earlier this month, Canada authorized distribution of the drug for chronic fatigue syndrome (see BioCentury May 6). HEMXU, which developed the product, will manufacture Ampligen. ...